产品名称:Anti-H_GDF15 hIgG4 Antibody(CTL-002) 目录价:询价 规格货号 GM-71274AB-10 10 μg GM-71274AB-100 100 μg GM-71274AB-1000 1mg 产品简介 Species ReactivityHuman CloneCTL-002 Source/IsotypeMonoclonal Human IgG1/κ ApplicationFlow Cytometry ...
In preclinical models CTL-002 demonstrated potent effector T cell shifting into tumor tissue by neutralizing GDF-15 and enhancing response to checkpoint inhibitor therapy. Methods: This is a phase 1, first-in-human (FIH), two-part, open-label clinical trial of intravenous (IV) administration of...
729MO Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatmentdoi:10.1016/j.annonc.2022.07.855I. Melero...
Here we report initial results of the phase 2a part of the GDF-15 neutralizing antibody visugromab (CTL-002) in combination with nivolumab. Methods: At cut-off date (06-Feb-2023), a total of 79 pts with advanced/metastatic solid tumors have been enrolled and were treated with visugromab...